aTyr Pharma (ATYR), a clinical-stage biotherapeutics company, announced on Tuesday, that the U.S. Food and Drug Administration has accepted its request for a Type C meeting. The meeting, scheduled for mid-April 2026, will focus on reviewing the results from the Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis.
During the meeting, the company plans to discuss the clinical data and determine the next steps for the program. aTyr expects to provide an update after receiving the official meeting minutes.
While the EFZO-FIT study did not meet its primary endpoint, the company noted a clinical benefit at the 5.0 mg/kg dose across multiple secondary measures.
These included improvements in patient-reported outcomes and maintenance of lung function, with a safety profile consistent with prior studies.
AYTR closed Monday's trading at $0.92 up $0.05 or 5.17 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.